Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases

Summary

Rona Therapeutics has entered into a global license agreement with Roche for an ALK7-targeting RNAi therapy targeting obesity and metabolic diseases. This partnership represents a significant validation of Rona's therapeutic approach in the high-interest obesity treatment space.